enGene Stock (NASDAQ:ENGN)

Forecast Ownership Financials Chart

Previous Close

$10.64

52W Range

$2.65 - $12.25

50D Avg

$8.52

200D Avg

$5.76

Market Cap

$623.04M

Avg Vol (3M)

$1.30M

Beta

-0.28

Div Yield

ENGN Company Profile

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Feb 01, 2022

Website

ENGN Performance

ENGN Financial Summary

	Oct 25	Oct 24	Oct 23
Revenue	-	-	-
Operating Income	$-123.17M	$62.30M	$-26.06M
Net Income	$117.30M	$-55.14M	$-99.92M
EBITDA	$-113.80M	$-52.04M	$-94.77M
Basic EPS	$-2.29	$-1.46	$-4.24
Diluted EPS	$-2.29	$-1.46	$-4.24

Fiscal year ends in Oct 25 | Currency in USD

Peer Comparison

Ticker	Company
ACIU	AC Immune S.A.
SLN	Silence Therapeutics plc
ALT	Altimmune, Inc.
ANNX	Annexon, Inc.
ANRO	Alto Neuroscience, Inc.
LRMR	Larimar Therapeutics, Inc.
DBVT	DBV Technologies S.A.
CLLS	Cellectis S.A.
AMRN	Amarin Corporation plc
KRRO	Korro Bio, Inc.